Transcriptomic alterations induced by all-trans retinoic acid in the Y79 retinoblastoma cell line+metagenome
All-trans retinoic acid has been demonstrated to induce upregulated CD38 expression in hematologic tumor cells, thereby enhancing the therapeutic efficacy of CD38-targeted immunotherapy in hematologic malignancies. However, the lack of specific therapeutic targets hinders the application of immunotherapy in retinoblastoma. To investigate whether ATRA exerts a similar impact on retinoblastoma, we treated Y79 retinoblastoma cell line with ATRA and assessed its influence on the transcriptome expression profile of Y79 cells to identify potential immunotherapeutic targets for retinoblastoma.